Search Results
Your search for it matches 15601 pages
Showing 7901 - 7950Physician-Patient Partnership Is Key to Recognizing and Managing Side Effects of Immune Checkpoint Inhibitors
“Immunotherapy has a completely different side-effect profile than chemotherapy, and that has caught physicians off guard,” noted Drew Pardoll, MD, PhD, in an article published earlier this year in The Washington Post.1 Since then, efforts have moved forward on several fronts to bring physicians,...
Undefeated
I’m sure every cancer survivor feels this way, but my diagnosis, in 1997, of stage III germ cell testicular cancer couldn’t have come at a worse time in my life. I was nearing the end of a 60-city tour with my figure skating show Stars on Ice, when a nagging pain in my abdomen became so severe I...
ASCO Commends Congress for NIH Funding
On March 23, 2018, ASCO President Bruce E. Johnson, MD, FASCO, issued the following statement: The American Society of Clinical Oncology (ASCO) applauds Congress for its bipartisan support of the omnibus spending bill that significantly boosts our nation’s investment in biomedical research. By...
More on the ABCSG-16 Trial
Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a shorter...
Extended Duration of Aromatase Inhibitors Need Not Be Very Long
At the 2017 San Antonio Breast Cancer Symposium (SABCS), Michael Gnant, MD, FACS, of the Medical University of Vienna presented the 9-year median follow-up of a trial looking at the length of extended aromatase inhibitor therapy. At least four other recently presented or published trials have...
Yale Cancer Center Launches Immuno-Oncology Center
Yale Cancer Center has launched the Yale Center for Immuno-Oncology. The new center will build on Yale Cancer Center’s international leadership in immunobiology, cancer immunology, and development of novel cancer immunotherapies. It is a partnership between Yale Cancer Center and the Department of...
Unstoppable
The following essay by Elias Jabbour, MD, is adapted, with permission, from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and...
Expert Point of View: Kathryn Ruddy, MD
“This is a very exciting study. Acupuncture is another tool to address arthralgias associated with aromatase inhibitor therapy,” said Kathryn Ruddy, MD, of the Mayo Clinic, Rochester, Minnesota. “I don’t think every patient with joint pain will opt for this for a variety of reasons, including...
SGO 2018: Participation in Clinical Trials May Overcome Health Disparities in Ovarian Cancer
Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a study presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting on Women’s Cancer (Abstract 6). The study evaluated the effect of ...
Acupuncture for Joint Pain Associated With Aromatase Inhibition
Although aromatase inhibitors are highly effective as adjuvant therapy in metastatic breast cancer and for prevention of breast cancer, the side effects can be difficult to tolerate and often lead to discontinuation of therapy. A phase III randomized trial has found that acupuncture may relieve...
IMpower150: Increased OS With Atezolizumab/Bevacizumab Plus Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower150 study met its coprimary endpoint of overall survival (OS) at interim analysis and showed that first-line treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced...
First Interim Analysis of Phase III SEQUOIA Trial in Pancreatic Cancer
ARMO BioSciences, Inc, recently announced the completion of the first interim analysis in its phase III SEQUOIA trial in patients with pancreatic cancer. The Data Monitoring Committee (DMC) for SEQUOIA, a clinical trial studying pegilodecakin (AM0010) plus FOLFOX (leucovorin,...
EBCC-11: MINDACT Trial: Patients With Early Breast Cancer and Risk of Locoregional Recurrence
Women with small, low-grade, well-defined breast tumors and a genetic profile that shows they are at low risk of the cancer metastasizing have only a 1.4% risk of locoregional recurrence within 5 years, according to new results from a large randomized trial of nearly 7,000 patients. This low risk...
AAD Issues Guidelines for Treatment of Nonmelanoma Skin Cancer
Skin cancer is the most common cancer in the United States, and nonmelanoma skin cancer is the most common type of skin cancer, affecting more than 3 million Americans every year. Moreover, nonmelanoma skin cancer incidence is growing at an exponential rate—between 1976–1984 and...
SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer
A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers...
EBCC-11: Sentinel Lymph Node Biopsy in Triple-Negative and HER2-Positive Breast Cancers
Sentinel lymph node biopsies may be safely avoided for some women, according to research presented at the 11th European Breast Cancer Conference (EBCC-11). Two new studies show that women with either triple-negative or HER2-positive types of breast cancer, whose cancers respond well to chemotherapy ...
FDA Expands Approval of Blinatumomab for Certain Patients With B-Cell Precursor ALL
The U.S. Food and Drug Administration granted accelerated approval to blinatumomab (Blincyto) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). In patients who have achieved remission after...
Study Cites Geographic Disparities in Lung Cancer Mortality Rates Among Women
According to the American Cancer Society, lung cancer is the leading cause of death among men and women, killing about 84,000 men and 71,000 women each year. Although lung cancer–related death rates in the United States have declined steadily since 1990 in men, they did not start to decline...
SSO 2018: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
Frozen section evaluation of sentinel lymph nodes after neoadjuvant chemotherapy has a higher false-negative rate than in the primary surgical setting, particularly for small tumor deposits. However, it is unknown whether similar false positive rates occur after chemotherapy. Researchers led by...
EBCC-11: Double Mastectomy in BRCA1 and BRCA2 Carriers
Healthy women who carry a breast cancer–causing mutation in the BRCA1 gene not only reduce their risk of developing the disease but also their chances of dying from it if they have both breasts removed, according to new research presented at the 11th European Breast Cancer Conference...
FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
On March 26, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy ...
SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination
Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendation, according to a study presented at the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting ...
SSO 2018: Improved Survival With Nodal Downstaging in Gastric Cancer if ypN0 Is Achieved
A team of researchers led by Naruihiko Ikoma, MD, MS, of The University of Texas MD Anderson Cancer Center in Houston, analyzed outcomes in 316 patients with gastric cancer to determine whether patients who had clinically positive nodal disease before preoperative therapy have...
Lenvatinib Mesylate Approved in Japan for Unresectable HCC
On March 23, the multiple-receptor tyrosine kinase inhibitor lenvatinib mesylate (Lenvima) was approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide of lenvatinib mesylate for the indication of unresectable HCC and the first new systemic therapy to...
EBCC-11: DCIS Less Likely to Recur in Patients Who Are Postmenopausal, ER-Positive
Patients with ductal carcinoma in situ (DCIS) are less likely to have recurrent disease if they are postmenopausal or if their tumor is estrogen receptor (ER)-positive, according to research presented at the 11th European Breast Cancer Conference (EBCC-11) (Abstract 215). DCIS accounts for about...
EBCC-11: Risk of a Second Breast Cancer Can Be Better Quantified in Patients With a BRCA Mutation
The risk of a second breast cancer in patients with high-risk BRCA gene mutations can be more precisely predicted by testing for several other genetic variants, each of which are known to have a small impact on breast cancer risk, according to new research presented at the 11th European Breast...
We Need to Fill the Gap Between Pediatric and Adult Oncology Care
When I was 15, and just 6 weeks into my sophomore year in high school, I heard a loud sound similar to a gunshot in my head and minutes later I was engulfed in a grand mal seizure, now called tonic-clonic seizure, and rushed to the hospital. A magnetic resonance imaging (MRI) scan found a small...
When Is Active Surveillance Appropriate in the Treatment of DCIS?
In 2017, more than 63,000 women in the United States were diagnosed with in situ breast cancer. The overwhelming majority of those women, about 83%, were diagnosed with ductal carcinoma in situ (DCIS), a condition characterized by the presence of abnormal cells confined to the breast milk ducts;...
Duration of Adjuvant Oxaliplatin-Based Therapy for Stage III Colon Cancer
“At Microphone 1” is an occasional column written by Steven E. Vogl, MD, of the Bronx, New York. When he is not in his clinic, he can generally be found at major oncology meetings and often at the microphone, where he stands ready with critical questions for presenters of new data. The opinions...
Long-Term Risk of Cardiovascular Disease Increased Among Colorectal Cancer Survivors
COMPARED TO the general population, the risk of cardiovascular disease among colorectal cancer survivors was significantly increased more than 10 years after their cancer diagnosis, according to research presented by David Baraghoshi, MSTAT candidate, of the Huntsman Cancer Institute at the...
CancerCare Publishes New White Paper on the Provider Perspective in Treatment Decision-Making
CANCERCARE has announced the publication of a new white paper highlighting perspectives from oncology providers on the importance and utility of including patient priorities in treatment decisions. “Decision Making at the Point of Care: Voices of Oncology Providers” was developed as part of...
Raising Awareness of the Link Between Alcohol and Cancer
Prevention in Oncology is guest edited by Jennifer Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber Cancer...
Breast Cancer Care in U.S. Territories Seems to Lag Behind Care in Continental United States
OLDER WOMEN residing in U.S. territories are less likely to receive recommended or timely care for breast cancer compared with similar women residing in the continental United States, according to Yale researchers, whose findings were published in Health Affairs.1 “Inferior breast cancer care in...
EXPERT POINT OF VIEW: Kenneth C. Anderson, MD, and S. Vincent Rajkumar, MD
AT A PREMEETING webinar, American Society of Hematology then President Kenneth C. Anderson, MD, Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute, Boston, commented: “This study demonstrates this new treatment has good...
Unique CAR T-Cell Construct Studied in Multiple Myeloma
CD19-DIRECTED chimeric antigen receptor (CAR) T-cell therapy has been approved by the U.S. Food and Drug Administration for the treatment of leukemia (tisagenlecleucel [Kymriah]) and lymphoma (axicabtagene ciloleucel [Yescarta]), but another type of CAR T-cell therapy is generating interest as a...
FDA Updates Public Information About Known Risk of Lymphoma From Breast Implants
On March 21, the U.S. Food and Drug Administration (FDA) issued updated information about its understanding of breast implant–associated anaplastic large cell lymphoma (ALCL). The agency is providing an updated number of medical device reports (ie, adverse event reports) and medical...
EAU 2018: Prostate MRI Reveals More Clinically Significant Cancers, Reduces Overdiagnosis Compared to Standard Biopsy
A large international study has shown that magnetic resonance imaging (MRI) can reduce the number of invasive prostate biopsies by up to 28%. The PRECISION trial showed that using MRI to target prostate biopsies leads to more harmful and fewer harmless prostate cancers being diagnosed. The results...
EAU 2018: Study Finds a Quarter of Penile Cancer Patients Do Not Receive Recommended Treatment
A major international survey has found that around a quarter of patients with penile cancer are not receiving the recommended treatment, and that these patients had half the survival rate of those who were treated according to guidelines. The study, presented at the European Association of Urology...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
How do patients really feel when they are in your care? What does it feel like to cure cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series Your Stories:...
ASCO International: 2017 Year in Review
In late 2016, ASCO announced further expansion of its robust portfolio of international programs, and significant progress toward this expansion was achieved in 2017. All of these accomplishments reflect the hard work and commitment of many ASCO member volunteers, ASCO staff, and organizations...
ASCO Advocate of the Year Stresses Importance of Congressional Advocacy on ASCO in Action Podcast
Robin Zon, MD, FACP, FASCO, the current Chair of ASCO’s Government Relations Committee and this past year’s ASCO Advocate of the Year, joins ASCO CEO Clifford A. Hudis, MD, FACP, FASCO, to discuss Congressional advocacy and the role it plays in shaping cancer-related policies. She explains how...
Martin S. Tallman, MD, Joins Samuel Waxman Cancer Research Foundation’s Scientific Advisory Board
The Samuel Waxman Cancer Research Foundation (SWCRF) announced that Martin S. Tallman, MD, Chief of Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has joined its Scientific Advisory Board. Dr. Tallman, who will continue in his role at MSK, will join his fellow Scientific...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
TAILORx Trial Results Aid in Assessing the Effect of Chemotherapy in Women With Early-Stage Breast Cancer
On March 15, Genomic Health, Inc, was informed by the ECOG-ACRIN Cancer Research Group that the TAILORx trial, has achieved sufficient information to render a conclusion regarding the efficacy of chemotherapy in patients with early-stage breast cancer who have Oncotype DX recurrence score...
Study Finds Shared Decision-Making Still Lacking in Prostate Cancer Screening
A new study found many men receiving prostate-specific antigen (PSA) testing do so without a comprehensive shared decision-making process, contrary to current guidelines. The American Cancer Society study, published by Fedewa et al in Annals of Family Medicine, found that in both 2010 and 2015,...
Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers
Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...
Studies Explore Colon Tumor Sidedness, Lung Radiation Dose in Esophageal Cancer, Pembrolizumab in Liver Cancer, and More
Along with full coverage of key presentations from the 2018 Gastrointestinal Cancers Symposium, The ASCO Post brings our readers this additional news roundup. Side Matters in Colon Cancer One of the studies included in the global IDEA trial, which compared 3 vs 6 months of adjuvant chemotherapy in ...
Expert Point of View: Malcolm K. Brenner, MD, PhD
Discussant for the abstract, Malcolm K. Brenner, MD, PhD, of Baylor College of Medicine Texas Children’s Hospital, underscored the need to make chimeric antigen receptor (CAR) T-cell therapy both safer and more effective. He also noted that overcoming antigen loss with multiple CARs is the next...
Testicular Cancer Survivors and Adequate Screening for Long-Term Heart Disease
Testicular cancer is the most common cancer in young men. The majority of patients are cured of their disease, but a newly published study shows many remain at risk for later complications from chemotherapy or other treatments. The study, published by Zaid et al in JNCCN –Journal of the...
ASTRO Issues New Clinical Guideline for Whole-Breast Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the use of whole-breast radiation therapy for breast cancer that expands the population of patients recommended to receive hypofractionated treatment. The guideline was published by Smith et al in...
